Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.
Merck Discontinues KeyVibe-010 Trial of Vibostolimab/Pembrolizumab in Resected High-Risk Melanoma
FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
Immunogenomics Demonstrate Predictive Capability to Immunotherapy Resistance in Uveal Melanoma
CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice
OBX-115 With Acetazolamide Induces Safe and Durable Antitumor Responses in Advanced Melanoma
Uveal Melanoma Immunogenomic Score Shows Predictive Potential
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer